Owing to its excellent insulin delivery profile at hyperglycemia and capability of preserving the bioactivity of insulin, the proposed MN patch is of great potential for minimally‐invasive administration of insulin, as confirmed via in vivo experiments. The gene discussed is INS; the disease is Hyperglycemia.